Nonchemotherapeutic therapies such as tyrosine kinase inhibitors are proving valuable in children and adolescents with acute lymphoblastic leukemia, according to a recent review. The authors note that although current treatments confer favorable prognosis, multiagent chemotherapy regimens are linked with complications, and therapy for relapsed disease is intensive and often not optimal.

The review goes on to summarize promising results from recent clinical trials of novel nonchemotherapeutic treatments, which can be used in conjunction with, or even in place of, current regimens.